Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23856894 | 0.89 | CYP3A4 (0.32) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL9886683 | 0.87 | CYP3A4 (0.31) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL15300042 | 0.81 | SMYD2 (0.31) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL30897924 | 0.80 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL12621518 | 0.80 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL14999549 | 0.80 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL31382508 | 0.80 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2456643 | 0.79 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL9468800 | 0.79 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL9468934 | 0.79 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727248-B2 | N-(4-CHLOROBENZYL)-8-(3-HYDROXY-1-PROPYNYL)-1-METHYL-6-(4 -MORPHOLINYLMETHYL)-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDE, FOR TREATING INFECTIONS BY HERPES VIRUSES | PHARMACIA & UPJOHN COMPANY | 2004-04-27 | — | — | US | disclosed |
| EP-1363887-A1 | SUBSTITUTED QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030149035-A1 | Substituted quinolinecarboxamides as antiviral agents | VAILLANCOURT VALERIE A (US) | 2003-08-07 | — | — | US | disclosed |
| US-6544990-B2 | Substituted quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20020165253-A1 | Substituted quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-11-07 | — | — | US | disclosed |
| WO-2002070487-A1 | SUBSTITUTED QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149035-A1 | Substituted quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, EIF2AK2 | CYP3A4 808/4885HTT 3670/4885SMN1; SMN2 4349/4885 |
| US-20020165253-A1 | Substituted quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, EIF2AK2 | CYP3A4 808/4885HTT 3670/4885SMN1; SMN2 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.